TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06197620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture and standard therapy
Description: In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
Study: NCT04832880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet [Olumiant]
Description: Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet [Olumiant]
Description: Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 6 mg for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 6 mg for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 6 mg for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 6 mg for 10 days
Study: NCT05880173

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FIB4
Description: Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography
Study: NCT05995899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
Study: NCT05260762

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arabinoxylan
Description: Dietary fiber product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Potato starch
Study: NCT04703491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive and full-featured intervention
Description: Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
Study: NCT06457841

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Hassles
Description: Day-to-day stressors associated with school, work, finances
Study: NCT05990400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: finasteride topical 0,1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil
Description: minoxidil topical 5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: minoxidil topical 5%
Study: NCT06301711

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT04703491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feature-limited CCBT
Description: Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: Participants will be put on a waitlist for a period of 6 weeks.
Study: NCT06352450

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Active isolated stretching (AIS)
Description: Active isolated stretching (AIS) is a technique that involves stretching specific muscles or muscle groups while actively engaging the opposing muscles. It typically involves holding a stretch for 1-2 seconds and then releasing. This method aims to improve flexibility, increase range of motion, and enhance muscle function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Description: Myofascial release (MFR) is a technique used to release tension and tightness in the fascia, which is the connective tissue that surrounds and supports muscles and organs. It involves applying gentle, sustained pressure to specific areas of the body to help relax the fascia and alleviate restrictions. MFR aims to improve mobility, reduce pain, and enhance overall movement and function.
Study: NCT05377944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2306
Description: 150 mg/1 ml/injection (2 injections/visit)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Cosentyx
Description: 150 mg/1 ml/injection (2 injections/visit)
Study: NCT06153472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-based intervention
Description: The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
Study: NCT06388317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Step Goal (Intervention)
Description: Receiving automated personalized daily step goals,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Step Goal (Control)
Description: Receiving fixed daily step goals of 10,000 steps per day
Study: NCT04790071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy plus dry needling
Description: Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
Study: NCT01471925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazol (40mg) + Sdium Bicarbonate (721mg)
Study: NCT05826847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone Positioning
Description: Prone positioning will be performed according to ICU local protocol with trained provider teams.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal Binding
Description: Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
Study: NCT05340790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Description: Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Description: Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Study: NCT04944524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.
Study: NCT05338931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
Description: Anti-CD19 Chimeric Antigen Receptor T cell
Study: NCT05952531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image IIM lesions in skeletal muscle, heart, lung, skin and potential tumor by PET/CT.
Study: NCT04787354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 2,000 mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 2,000 mg/m2/day
Study: NCT05793242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypervolt
Description: HyperVolt Percussive Massage Device: this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a vibrating device to the back of the thigh with moderate pressure while continuously moving the device for 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Tempering
Description: Body Tempering:this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a moderately heavy metal device to the back of the thigh while continuously moving the device for 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry cupping
Description: Dry Cupping: This will be performed by a physical therapist while the participant is prone. The physical therapist will apply several negative pressure devices to the back of your thigh for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching
Description: Participants will perform a static stretch on their lower extremity. This stretch will be performed by having the participant loop a strap around their heel and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will be instructed to lift the leg until they reach their maximal tolerable point and then to hold the position for 30 seconds. They will then lower the extremity to the table and rest for 15 seconds This self-stretch sequence will be performed for 7 cycles so that the total intervention was equal to the intervention time of the other group (5 minutes).7
Study: NCT04833595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Description: Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness practice
Description: Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
Study: NCT05084898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Far-UVC light as an additional method of disinfection
Description: Far-UVC light is a form of ultraviolet light with an extremely short wavelength (222 nm)
Study: NCT04783805

Intervention type: DIAGNOSTIC_TEST
Intervention: Conservative management with regular follow-up
Description: Women will be followed-up every 4 months, with colposcopy and cytology at each visit.

Intervention type: PROCEDURE
Intervention: Conization
Description: Women with progression of HSIL, HSIL persistence after 24 months of follow-up, or that no longer meet the criteria for surveillance will have conization
Study: NCT06463951

Intervention type: OTHER
Intervention: Psychotherapy - Gestalt psychotherapy
Description: Gestalt psychotherapy is an aesthetic-phenomenological approach that aims to improve self-awareness and integration by promoting emotional and relational well-being through what is happening in the present moment in the relationship with the therapist. The patient's current experiences are explored to better understand problems and behaviors and by promoting relational self-regulation
Study: NCT05084898

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fluorescent light
Description: Inactive fluorescent light (no additional disinfection)
Study: NCT06339970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique
Description: In this group 21 patients will perform Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique
Description: In this group 21 patients will perform Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
Study: NCT05704660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusted Cognitive-biased modification task
Description: The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-biased modification task
Description: In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
Study: NCT04702425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOB560
Description: Powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOB560
Description: Powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOB560
Description: Powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOB560
Description: Powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOB560
Description: Powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOB560
Description: Powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: Concentrate for solution for infusion
Study: NCT05533320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Cap Therapy
Description: Undergo scalp cooling
Study: NCT04865380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: 1g IV x 1 dose of Tranexamic Acid administered preoperatively.
Study: NCT04901195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT04862689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ringer Perfusion Balloon Catheter
Description: Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
Study: NCT05217004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Talk mobile application
Description: The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
Study: NCT05533320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies